Alloy Therapeutics

Edit info

Founded: 2018

Location: Waltham, MA

Employee range: 50 - 200

Clinical stage: RD

Therapy area: Drug discovery

Drug types: IMM

Lead product: Alloy-Gx mouse platform

Funding: $42M D Oct 2022; $75M C Apr 2021

Investors: 8VC, Mubadala Capital, Thiel Capital, Presight Capital, Founders Fund

alloytx.com

linkedin.com

job board

Business:

Antibody Discovery Platform

Drug notes:

Also offer services for antibody discovery and development

About:

Alloy Therapeutics describes itself as a biotechnology ecosystem company that enables pre-competitive drug discovery at all levels. Alloy currently offers licensing in antibody and TCR platforms, drug discovery and optimization services, and subscription-based access to pre-competitive technology. Alloy utilizes highly immunocompetent transgenic mice to produce maximum diversity and epitopic coverage with their ATX-Gx antibody platform. They also offer their ATX-CLC platform for common-light chain bispecific and multispecific discovery as well as their ATX-SiD platform for the discovery of single-domain antibodies. The Keyway TCR Discovery Services offer access to custom therapeutic TCR mimics and engineered TCRs against custom targets.